RxDoctor Payments Data

Gina Moran, MD

Internal Medicine · Dubuque, IANPI 1619946084

Payments from drug & device makers

$598in general payments, 2019–2025

Across 29 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$146
  • Pfizer$74
  • Lilly USA, LLC$60
  • AstraZeneca$47
  • Novo Nordisk$42
  • Exact Sciences$31
  • plus $198 from 10 others

What the payments were for

  • Food & beverage$49983%
  • Education$9917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$598 in reported general payments places this provider in the 80th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$137,461
Medicare patients
295
Services billed
3,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin174$170,407
EliquisApixaban144$149,828
OzempicSemaglutide62$54,751
XareltoRivaroxaban44$47,081
FarxigaDapagliflozin Propanediol30$27,819
MounjaroTirzepatide27$26,508
CreonLipase/Protease/Amylase11$18,209
MyrbetriqMirabegron22$15,615
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,811
Spiriva RespimatTiotropium Bromide15$10,860
VeozahFezolinetant11$5,905
BelsomraSuvorexant12$5,191
Potassium Chloride166$4,286
Losartan Potassium407$4,103
Atorvastatin Calcium428$4,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$149,828144 claims
Novo NordiskOzempic$42$54,75162 claims
Johnson & JohnsonXarelto$23$47,08144 claims
AstraZenecaFarxiga$47$27,81930 claims
Lilly USA, LLCMounjaro$60$26,50827 claims
Astellas Pharma US IncMyrbetriq, Veozah$146$21,51933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Dubuque

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →